Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Definitive Chemoradiotherapy With or Without Immunotherapy/Targeted Therapy for Esophageal/Esophagogastric Cancer
NCT04821778Phase 3Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Jan 2002
- Primary completion
- Dec 2030
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of nimotuzumab in esophageal cancer, esophagogastric junction cancer, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Started Jan 2002; status: recruiting.
02
Drugs
nimotuzumab
03
Conditions
esophageal canceresophagogastric junction cancer
Beyond the preview
Go deeper on NCT04821778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04821778.